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ABSTRACT (R)-Hexahydro-difenidol has a higher affinity for M1 receptors in 
NB-OK 1 cells, pancreas M3 and striatum M4 receptors (pKi 7.9 to 8.3) than for 
cardiac M2 receptors (pKi 7 .0). (8)-Hexahydro-difenidol, by contrast, is nonselective 
(pKi 5.8 to 6.1). Our goal in the present study was to evaluate the importance ofthe 
hydrophobic phenyl, and cyclohexyl rings of hexahydro-difenidol for the stereose-
lectivity and reeeptor selectivity of hexahydro-difenidol binding to the four mus-
carinic receptors. Our results indieated that replacement of the phenyl ring of 
hexahydro-difenidol by a cyclohexyl group <~ dicyclidol) and ofthe cyclohexyl ring 
by a phenyl moiety <~ difenidol) indueed a !arge (4- to 80-fold) decrease in binding 
affinity for all musearlnie receptors. Difenidol had a signifieant preference for M1 , 
M3 , and M4 over M2 receptors; dicyclidol, by eontrast, had a greater affinity for M1 
and M4 than for M2 and M3 receptors. The binding free energy deerease due to 
replacement ofthe phenyl and the cyelohexyl groups of(R)-hexahydro-difenidol by, 
respectively, a eyclohexyl and a phenyl moiety was almostadditive in the ease of 
M4 (striatum) binding sites. In the ease ofthe cardiac M2, pancreatic M3 , or NB-OK 
1 M1 receptors the respective binding free energies were not eompletely additive. 
These results suggest that the four (R)-hexahydro-difenidol ''binding moieties" 
(phenyl, cyclohexyl, hydroxy, and protonated amino group) cannot simultaneously 
form optimal interaetions with the M1, M2, and M3 muscarinic receptors. When 
eaeh of the hydrophobic groups is modified, the position of the whole molecule, 
relative to the four subsites, was changed to allow an optimal overall interaction 
with the musearlnie receptor. 
KEY WORDS: hexahydro-difenidol enantiomers, muscarinic receptor subtypes 
M1, M2, M3 , and M4, stereoselective interaction, difenidol, dicyeli-
dol 
INTRODUCTION 
At least three pharmacologically and structurally 
distinct muscarinic receptors eoexist in mammalian 
tissues.1•2 M1 receptors, with a high affinity for piren-
zepine, are typically found in neuronal tissues. 3 These 
receptors have a low affinity for AF-DX 116 
(11-( { (2-[ ( diethy lamino )methy l]-1-pi peridiny I }acety D-
5-11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-
6-one) and a high affinity for 4-DAMP (4-
diphenylacetoxy-N-methylpiperidine methiodide) and 
hexahydro-sila-difenidol. 4- 6 M2 receptors, with a low 
affinity for pirenzepine and a high affinity for AF-DX 
116, are typical of eardiac tissues.7 They show a .low 
affini ty for 4-DAMP and hexahydro-sll a-
difenidol."-6·8·9 M3 receptors have low affinities for 
(Cl 1991 Wiley-Liss, Inc. 
pirenzepine and AF-DX 116, and high affinities for 4-
DAMP10 and hexahydro-sila-difenidol. 5 •6·9 They are 
typically detected in secretory glands11 •12 and in 
smooth muscle. 1•2 •9 
There is a candidate M4 receptor found in rat stria-
tum (previously called "B" sites) which differs from M3 
receptors by its high affinity for himbacine and 
methoctramine.13 
Hexahydro-difenidol (Fig. 1) is weil characterized as 
ileum-preferring musearlnie antagonist (high affinity 
for M3 receptors). It recognizes M3 receptors (in smooth 
muscle or secretory glands) with a 10- to 30-fold 
Received for publication July 30, 1990; accepted December 10, 1990. 
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Fig. 1. Chemical structure of (R)- and (8)-hexahydro-difenidol, difenidol, and dicyclidol. 
greater affinity than M2 receptors.5•6 •9 Wehave already 
demonstrated that muscarinic receptors are capable of 
discriminating the two enantiomers of hexahydro-
difenidol, and have a greater affinity for the (R)-
enantiomer. 14•22 
In a previous study on the stereoselective binding of 
procyclidine enantiomers, we suggested that muscarin-
ic receptor subtypes possess four binding subsites for 
antagonists.15 One of these "subsites" is the ionic bind-
ing site recognizing the protonated amino group of pro-
cyclidine; the second, a polar site forming a hydrogen 
bond with the procyclidine hydroxy group, and the two 
hydrophobic binding sites recognizing, respectively, 
the phenyl or the cyclohexyl groups of (R)-procyclidine 
with a greater affinity. Our results further indicated 
that when (8)-procyclidine is brought into contact with 
the receptor, the ionic and hydroxy groups are in the 
correct position, and the phenyl and the cyclohexyl 
groups in contact, respectively, with the cyclohexyl-
preferring and phenyl-preferring subsites.15 
Given the great structure homology of procyclidine 
and hexahydro-difenidol, we expected that the procy-
clidine binding model should also be applicable to 
hexahydro-difenidol (Fig. 2). To test this hypothesis, 
we decided to measure the affinity of two achiral com-
pounds structurally related to hexahydro-difenidol: 
difenidol (containing an additional phenyl moiety in-
stead of the cyclohexyl group) (Fig. 1) and dicyclidol 
(containing an additional cyclohexyl moiety instead of 
the phenyl group). We hoped to measure the difference 
of binding energy of a phenyl versus cyclohexyl group 
with each hydrophobic subsite. 
MATERIALS AND METHODS 
Drugs 
[3H]NMS [1-(N-methyl-3H)scopolamine methochlo-
ride, 80 to 85 Ci/mmol] was obtained from Amersham 
International (Bucks, England). Atropine sulfate and 
polyethyleneimine were from Sigma Chemical Co. (St. 
Louis, MO). All the other reagents were ofthe highest 
Fig. 2. Interaction of protonated (R)-hexahydro-difenidol with four 
subsites of the muscarinic receptor. Asp, aspartate residue.23 
grade available. All antagonists tested were synthe-
sized in our laboratories. The hexahydro-difenidol en-
antiomers were prepared as previously published, 16 
difenidol was synthesized according to the literature, 17 
and dicyclidol was obtained by analogy to the synthesis 
of (R)- and (8)-hexahydro-difenidol16 starting from di-
cyclohexyl ketone (unpublished results). The enantio-
meric excess (ee) of (R)- and (S)-hexahydro-difenidol 
was >99.8%, determined by calorimetric analysis. 16 
Homogenate Preparations 
Human NB-OK 1 neuroblastoma cells were cultured 
in RPMI 1640 medium enriched with 10% foetal calf 
serum, 100 units/ml penicillin, and 100 ~g/ml 
streptomycin.4 For [3H]NMS binding experiments, the 
cells were rinsed, detached, and centrifuged in 20 mM 
sodium phosphate buffer (pH 7 .4) containing 150 mM 
NaCl and 1 mM EDTA, resuspended and homogenized 
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in 20 mMTris~HCl buffer (pH 7.5) enriched with 5 mM 
MgCl2 , and stored in liquid nitrogen until use. 
To prepare rat tissue homogenates, male Wistar al-
bino rats (200-250 g) were killed by decapitation and 
the heart, pancreas, and striatum immediately re-
moved. Homogenate preparations were perfonned at 
4°C. The heart was rinsed in isotonic NaCl, then ho-
mogenized in 2.5 ml of20 mMTris~HCl buffer (pH 7.5), 
enriched with 250 mM sucrose, with an Ultraturrax 
homogenizer (maximal speed for 5 sec) followed by ad~ 
dition of 12.5 ml of the same buffer, 7 up and down 
strokes with a glass-Teflon homogenizer, and filtration 
on 2 layers of medical gauze. The resulting homogenate 
was used immediately or stored in liquid nitrogen until 
use. The striatum was homogenized in 2 ml of 20 mM 
Tris-HCI buffer (pH 7.5) enriched with 250 mM su-
crose, using a glass-Teflon homogenizer (7 up and down 
strokes). The resulting homogenate was stored in liq-
uid nitrogen until use, and diluted 20-fold with the 
same buffer immediately before the experiment. The 
pancreas was minced with scissors, homogenized with 
a glass-Teflon homogenizer in 8 ml of 300 mM sucrose 
enriched with Trasylol (500 KIU/ml) and bacitracin 
(0.2 mg/ml). The resulting homogenate was immedi-
ately filtered on two layers of medical gauze and di-
luted 11-fold with an incubation buffer made of66 mM 
sodium phosphate (pH 7 .4), 2.6 mM MgC12 , 500 KIU/ml 
Trasylol, 0.2 mg/ml bacitracin, and 13 mg/ml bovine 
serum albumin. 
Receptor-Binding Studies 
Binding sturlies were performed at 25°C in a 50 mM 
sodium phosphate buffer (pH 7.4) enriched with 2 mM 
MgC12 and containing [3H]NMS and the indicated un-
labelled drug concentrations in a total volume of 1.2 
ml. For pancreas binding studies, the incubation buffer 
also contained bovine serum albumin (1% w/v), baci-
tracin (0.2 mg/ml), and Trasylol (500 KIU/ml) to pre-
vent receptor degradation. 
To measure [3H]NMS binding to human NB-OK 1 
cell homogenates, we used 80 JJ.l of homogenate, corre-
sponding to about 200 ,...g protein per assay. The incu-
bation period was 2 h in the presence of 0.25 nM 
[3H]NMS in order to allow binding equilibrium. This 
[3H]NMS concentration was equivalent to 2-fold the 
tracer's K 0 value at M1 receptors.4 For incubation with 
rat heart homogenates, we used 80 JJ.l of the homoge-
nate, corresponding to 400-500 J.l.g protein per assay. 
The 2-h incubation periodwas sufficient to allow equi-
librium binding. The [3H]NMS concentration used was 
1.0 nM, i.e., 2-fold the tracer's K0 value at M2 binding 
sites. 8 In rat striatum homogenates, [3H]NMS Iabels 
M1 and M4 sites but dissociates faster from M1 
receptors.4•8•18 We preincubated 80 JJ.l of the homoge-
nate (equivalent to about 30 JJ.g protein) in a total vol-
ume of 1.2 ml in the presence of [3H]NMS and unla-
beled drugs. A 2-h preincubation period allowed equi-
librium binding. We then added 1 ~ atropine and let 
tracer dissociation to proceed for 35 min before filtra-
tion. This procedure permitted us to investigate tracer 
binding to striatum M4 ("B") receptors only. 4•8 The 
tracer concentration used in these experiments (0.25 
nM) was equivalent to 5-fold the tracer's K0 value at 
striatum M4 receptors. 8 For incubation with rat pan-
creas homogenate, we added 980 JJ-l of homogenate to 
220 ,...1 drug and tracer (in water). A 4-h incubation 
periodwas necessary to allow equilibrium binding. 11 
The [3H]NMS concentration used was 0.24 nM, i.e., 2-
fold the tracer's K 0 value at pancreas M3 binding 
sites.11 All incubations were terminated by addition of 
2 ml of ice-cold filtration buffer (50 mM sodium phos-
phate buffer, pH 7.4). Bound and free tracer were im-
mediately separated by filtration on GF/C glass-fiber 
filters (Whatman, Maidstone, England) presoaked 
overnight in 0.05% polyethyleneimine. The samples 
were rinsed three times with filtration buffer. The fil-
ters were then dried, and the bound radioactivity 
counted by liquid scintillation. Nonspecific [3H]NMS 
binding was defined as tracer bound in the presence of 
1 JJM atropine. 
Protein concentration was determined according to 
Lowry et al.19 using bovine serum albumin as stan~ 
dard. 
Analysis of Binding Data 
All competition curves were repeated in duplicate, at 
least three times on different preparations. IC50 values 
were determined by a computer~aided procedure,20 as-
suming the existence of only one receptor subtype. In-
deed, experimental data points were within 3% of ex-
pected values, assuming that the molecules investi-
gated competed with [3H]NMS for binding to a single 
site. 
Ki values were calculated from IC50 values, using the 
Cheng and Prusoff equation21 which assumes compet-
itive inhibition of tracer binding to a single receptor 
subtype. The [3H]NMS K0 value for the four systems 
investigated was determined in separate experi-
ments.4·8·11 The pKi values, summarized in Table 1, 
corresponds to -log Ki values. 
The standard deviation of -log IC50 determination 
was equal to or below 0.1log unit. Repeated determi-
nations of[3H]NMSK0 values were within 10% ofeach 
other. This error should be added to errors in IC50 de-
terminations, since [3H)NMS K0 values were used to 
calculate pKi values. We therefore estimated the stan-
dard deviation of pKi values as being of approximately 
0.15 log unit (40% of Ki value). 
The binding free energy (~G) for the formation of a 
ligand-receptor complex is related to its affinity con-
stant Ka by Eq. (1): 
~G = -RT In K. (1) 
!lG values were therefore calculated according to Eq. 
(2), using experimentally determined Ki values (K8 = 
Ki -1): 
~G = -RT In l!K; 
RESULTS 
(2) 
As shown in Figures 3 and 4, the four compounds 
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Fig. 3. [3H]NMS competition curves in membranes from human 
neuroblastoma NB-OK 1 ceJls (upper panel) or rat heart (lower 
panel). [3H]NMS bindingwas measured in the absence or presence of 
(R)-hexahydro-difenidol (0), (S)-hexahydro-difenidol (e), difenidol 
(6), or dicyclidol (0), as described in methods. 
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Fig. 4. As in Figure 3, using rat pancreas (upper panel) and rat 
striatum (lower panel). 
investigated in this study inhibited [3H]NM8 binding 
to the four muscarinic receptors in a manner consistent 
with competition for a single binding site (Hili coeffi-
cients were not significantly different from unity). 
Tbe affinity oftbe hexahydro-difenidol eutomer, (R)· 
bexahydro-difenidol, for Mtt M3 , and M4 receptors was 
greater than its affinity for M2 receptors. The hexahy-
dro-difenidol distomer, (8)-bexahydro-difenidol, had a 
similar affinity for tbe four subtypes (Table 1, Figs. 3 
and 4). As a result, tbe eudismic index [(pKi (eutomer) 
- pKi (distomer)] at M1, M3 , and M4 receptors was 
greater tban tbat at M2 receptors (Table 1). 
Difenidol and dicyclidol had lower affinities than (R)-
bexabydro-difenidol and higber affinities than the (8)-
enantiomer at tbe four subtypes (Table 1). Difenidol 
bad a somewbat higher affinity for M1 , M3 , and M4 
sites as compared to M2 sites (5-fold selectivity). By 
contrast, dicyclidol bad a lower affinity for M2 and M3 (as compared to M1 and M4 ) sites. 
By contrast with our previous results with 
procyclidine, 15 tbe affinity Iosses due to replacement of 
tbe pbenyl ring by a cyclohexyl group and tbe cyclo-
bexyl ring by a pbenyl moiety in (R)-hexahydro-
difenidol were not fully additive. (8)-Hexabydro-
difenidol bad a 2- to 5-fold higher than "expected" af-
finity for M1, M2, and M3 receptors. Analysis of the 
binding properties of tbe 4 compounds in striatum B 
sites (M4 sites) indicate tbat, in this system, the affin-
ity loss was additive. 8ince the eudismic index of 
hexahydro-difenidol binding to M1 and M4 sites is com-
TABLE 1. Comparison of binding affinities (pKi values) of 
(R)-hexahydro-difenidol, (S)·hexahydro-difenidol, 
difenidol, and dicyclidol for four muscarinic 
receptor subtypes• 
M1 M2 M 3 M4 (NB-OK 1) (heart) (pancreas) (striatum) 
(R)-Hexahydro-
difenidol 8.3 7.0 8.1 7.9 
Difenidol 7.1 6.4 7.1 7.2 
Dicyclidol 6.8 6.1 6.2 6.8 
(8)-Hexahydro-
difenidol 6.1 5.8 5.9 5.9 
pKi difference 
(eudismic index) 
[(R) ~ (8)] 2.2 1.2 2.2 2.0 
(R)-Procyclidine 8.4 7.3 8.1 
Pyrrinol 7.5 6.9 7.2 
Hexahydro-
procyclidine 7.1 6.1 7.0 
(8)-Procyclidine 6.3 5.8 6.0 
pKi difference 
(eudismic index) 
[(R) ~ (8)] 2.1 1.5 2.1 
"'''he pKi values of (R)-procyclidine, (S)-procyclidine, pyrrinol, and 
hexahydro-procyclidine found in a previous work15 are shown for com-
parison. 
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~arable, our results cannot be explained by contamina-
tlon of (8)-hexahydro-difenidol by the (R)-enantiomer. 
DISCUSSION 
We have previously shown that the stereoselective 
binding of the enantiomers of procyclidine to musca-
rinic binding sites is best explained by the existence of 
four subsites (Fig. 2): one for the protonated amino 
group, one for the hydroxy group, one phenyl-
preferring hydrophobic subsite, and one cyclohexyl-
preferring hydrophobic subsite.t5 The relative spatial 
positions of these four subsites is such that (R)-
procyclidine has a greater affinity than (8)-
procyclidine due to a better interaction of the hydro-
phobic groups with their corresponding subsites. The 
free energy of (R)-procyclidine binding can therefore be 
described by Eq. (3): 
4.G = a4G1 + ß4G2 + -y4.G3 + 84.G4 (3) 
where ÄGtt ÄG2, 6.G3, and 6.G 4 represent the free en-
ergy achievable by an optimal interaction ofthe phenyl 
ring of the Iigand with receptor site 1, the cyclohexyl 
group with receptor site 2, the hydroxy group with re-
ceptor site 3, and the protonated amino group with re-
c~ptor site 4. tiG values should be as negative as pos-
sible to obtain high affinity binding, and factors cx, ß, -y, 
and 8 in Eq. (3) take into account the fact that all four 
groups are not of necessity simultaneously in the opti-
mal positions to interact with receptor sites 1 to 4 (cx, ß, 
-y, and 8 values probably vary between 0 and 1, pro-
vided that the corresponding group does not obstruct 
binding by steric hindrance). 
We compared in this work the binding properties of 
hexahydro-difenidol enantiomers and of two achiral 
analogues, difenidol and dicyclidol (Fig. 1) to four mus-
carinic receptor subtypes. Our results confirm that the 
presence of a phenyl and a cyclohexyl ring in the cor-
rect spatial position [(R)-configuration] is important for 
the binding ofhexahydro-difenidol to muscarinic recep-
tors. lndeed, the affinity decrease due to replacement of 
the cyclohexyl ring by a phenyl group varied between 
0.6 and 1.2 log units (corresponding to an increase of 
the binding free energy of0.8 to 1.6 kcal/mol) (Table 2). 
The affinity decrease due to replacement of the phenyl 
by a cyclohexyl ring was even more impressive. It 
amounted to 0.9 to 1.5log units (free energy difference: 
1.2 to 2.6 kcal/mol) (Table 2). 
The binding free energy decrease due to replacement 
of the phenyl and the cyclohexyl groups of (R)-
hexahydro-difenidol by, respectively, a cyclohexyl and 
a phenyl moiety was additive in case of M4 receptors 
(Table 2). 
In contrast with our previous results, using the pro-
cyclidine enantiomers (Tables 1 and 2), t5 this substitu-
tion effect was not fully additive at M1, M2, and M3 
receptors: the difference of the free energy of binding of 
(S)- and (R)-hexahydro-difenidol to Mt, M2 , and M3 sub-
types was lower than expected by up to 1 kcal/mol. 
These discrepancies were subtype dependent and not 
correlated with receptor stereoselectivity, indicating 
TABLE 2. Differences between the free energies«-
(kcal/mol) of binding of (S)-hexahydro-difenidol difenidol 
or dicyclidol and (R)-hexahydro-difenidol f~r four ' 
muscarinic receptor subtypes6 
MI M2 Ma M" (NB-OK 1) (heart) (pancreas) (striatum) 
Difenidol +1.64 +0.82 +1.36 +0.95 
Dicyclidol +2.05 +1.23 +2.59 +1.50 
Expectedc +3.69 +2.05 +3.95 +2.45 
(8)-Hexahydro-
difenidol +3.00 +1.64 +3.00 +2.73 
Pyninol +1.23 +0.55 +1.23 
Hexahydro-
procyclidine +1.77 +1.64 +1.50 
Expectedc +3.00 +2.19 +2.73 
(8)-Procyclidine +2.87 +2.05 +2.86 
"Binding free energies were calculated according to Eq. (2), see under 
methods. 
bThe differences between the free energies of binding of (S)-
procyclidine, pyninol, or hexahydro-procyclidine and (R)-procyclidine 
found in a previous work16 are shown for comparison. 
csum of the differences of the free energies of binding of (R). 
hexahydro-difenidol and difenidol and of (R)-hexahydro-difenidol and 
d.icyclidol. 
that they did not reflect an imperfect separation of the 
(R)- and (8)-enantiomers. They were small, when com-
pared with the free energy of binding of the drugs: at 
most 12% of the binding free energy of the (8)-
enantiomer to the receptors. 
We would like to suggest that by contrast with (R)-
procyclidine, the four subgroups ofhexahydro-difenidol 
cannot be simultaneously in the optimal position to 
interact with the corresponding four subsites of mus-
carinic M1, M2 , and M3 receptors. This corresponds in 
Eq. (3) to values ofthe parameters cx, ß, -y, and 8 <1.0. 
The results indicate that, when the structure of (R)-
hexahydro-difenidol is modified, e.g., by replacement of 
the phenylring in subsite 1 by a cyclohexyl group <~ 
dicyclidol), the position of dicyclidol in the receptor is 
adjusted to increase the importance of the (good) inter-
action with subsites 2, 3, and 4 at the expense of the 
(~eakened) interaction with subsite 1. Therefore, the 
d1fference of the free energy of binding of (R)-
hexahydro-difenidol and, for instance, difenidol or di-
cyclidol does not reflect exactly the modification of A.G1 
or 6.G2 values. The development of an interaction 
model using molecular modeling methods and based on 
published Mt, M2 , M3 , and M4 receptor protein 
sequences23 might provide an improved rationale for 
the stereoselective interactions of (R)- and (8)-
hexahydro-difenidol (this study), and of (R)- and (8)-
procyclidinet5 with muscarinic receptor subtypes. 
CONCLUSION 
The muscarinic receptor stereoselectivity for the 
hexahydro-difenidol enantiomers is probably ex-
plained at least in part by weaker binding ofthe phenyl 
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and cyclohexyl group of the (8)-isomer. The four (8)-
hexahydro-difenidol binding moieties (phenyl, cyclo-
hexyl, OH group, and protonated amino group), how-
ever, cannot simultaneously form optimal interactions 
with each of the corresponding four subsites of musca-
rinic receptors. The results indicate that the loss of 
binding affinity (increase of the free energy of binding) 
due to replacement ofthe phenyl and cyclohexyl groups 
was not fully additive when considering the M1, M2, 
and M3 sites. 
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